PTCT News 18.78 Ptc Therapeutics Inc (PTCT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ptc Therapeutics Inc (PTCT) 18.78 $PTCT

Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Why PTC Therapeutics, Inc. Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 12:37PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of PTC Therapeutics , a biopharmaceutical...

PTC Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
PR Newswire - Thu Mar 06, 3:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013.

Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.

PTC Therapeutics To Present At The Cowen & Company 34th Annual Health Care Conference
PR Newswire - Fri Feb 28, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Cowen & Company 34th Annual Health Care Conference on Wednesday, March 5th at 9:20 am ET at the Marriott Copley Plaza Hotel in Boston.

PTC Therapeutics announces inducement grant
M2 - Fri Feb 28, 3:38AM CST
US-based biopharmaceutical company PTC Therapeutics (NasdaqGS TCT) said on Thursday that it has awarded a non-statutory stock option to purchase 150,000 shares of its common stock.

PTC Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Thu Feb 27, 8:30PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it granted a non-statutory stock option to purchase 150,000 shares of its common stock to Robert Spiegel, M.D., PTC's newly appointed Chief Medical Officer. The grant was made pursuant to the NASDAQ inducement grant exception as a component of Dr. Spiegel's employment compensation. The inducement grant was approved by PTC's Board of Directors on February 27, 2014 and is being made as an inducement material to Dr. Spiegel's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). PTC previously announced that Dr. Spiegel has been appointed Chief Medical Officer, effective January 23, 2014.

PTC Therapeutics to Host Fourth Quarter and Year End 2013 Financial Results Conference Call
PR Newswire - Thu Feb 27, 4:45PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that will host a webcast conference call to discuss financial results for the fourth quarter and year end 2013 on Thursday, March 6, 2014 at 4:30 p.m. (ET) after the closing of the market.

PTC Therapeutics Expands International Commercial Team
PR Newswire Europe - Tue Feb 25, 7:02AM CST
PTC Therapeutics, Inc. today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC.

PTC Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Thu Feb 20, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences:

PTC Therapeutics Announces Closing of Registered Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Wed Feb 19, 12:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the closing of its previously announced registered public offering of 5,163,265 shares of its common stock, including 673,469 shares sold by PTC as a result of the full exercise by the underwriters of their option to purchase additional shares, at a price to the public of $24.50 per share. PTC expects its net proceeds from this offering to be approximately $118 million, after deducting the underwriting discounts and commissions and estimated expenses.

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth
M2 - Fri Feb 14, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ghfxl/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth" report to their offering. CFTR Modulators Instigate Cystic Fibrosis Market Surge The Cystic Fibrosis (CF) market will grow rapidly over the forecast period (2012-2019) at a Compound Annual Growth Rate (CAGR) of 30.6%. The sharp rise in market value is due to powerful new drugs entering the market, in particular the novel disease-modifying Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators. Although very expensive, CFTR modulators are the first to act directly on the defective CFTR protein, which is the root cause of CF. As a result they represent the closest therapy to a cure currently available for CF patients. One CFTR modulator, Kalydeco (ivacaftor), is currently on the market, although it can only treat 5% of people with a specific mutation (O'Reilly and Elphick, 2013). Despite the low treatment population, it has already become one of the top-grossing drugs since its launch in 2012. A second CFTR modulator, lumacaftor, is expected to be launched in 2015. This drug is used in combination with Kalydeco and it is expected to be usable in over 80% of the CF population, which, combined with its large cost and uptake is expected to be the primary driver in the CF market surge. Increasing Life Expectancy Causes Rise in Prevalence The prevalence of CF will rise slowly over the forecast period by an estimated 10,000 cases. The primary cause of this is the increasing life expectancy of CF patients, which has rapidly grown over the past three decades as the understanding of the causes of CF has developed (Davies et al., 2007). CF incidence remains relatively constant as it is a hereditary disease; however the mortality rate is decreasing due to improvements in treatments and disease management. Therefore, the overall mortality rate is lower than the birth rate of CF patients and so the CF population is increasing. This will eventually reach equilibrium. The increasing prevalence is also a factor in terms of driving market growth, as many CF therapeutics must be taken indefinitely and on a regular basis. Key Drug Expiries Instigate Competition Several key drug expirations will occur in the forecast period. The drugs set to lose their patent protection are the mucolytic Pulmozyme (dornase alfa) and the antibiotics TOBI (tobramycin) and TOBI Podhaler (tobramycin). Cheap, generic versions of TOBI and TOBI Podhaler are expected to enter the market following their patent expiration, leading to an increase in the number of antibiotics on the market and an increase in competition. The number of Pulmozyme biosimilars and the impact on pricing is expected to be limited. The antibiotics segment of the market is predicted to become overcrowded in the forecast period, following the launch of several products with similar safety and efficacy profiles and the introduction of generic TOBI and TOBI Podhaler. Rather than one product dominating the antibiotics segment as is currently the case with TOBI, it is likely that each new product will acquire a smaller but more equal market share. Key Topics Covered 1 Table of Contents 2 Introduction 2.1 Disease Introduction 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Diagnosis 2.6 Prognosis 2.7 Assessment of Disease Severity 2.8 Treatment 3 Marketed Products 3.1 Overview 3.2 Product Profiles 3.3 Heat Map of Marketed Products 3.4 Conclusion 4 Developmental Pipeline 4.1 Overview 4.2 Mechanisms of Action in the Pipeline 4.3 Clinical Trials 4.4 Promising Pipeline Molecules 4.5 Heat Map of Pipeline Products 4.6 Conclusion 5 Market Forecast to 2019 5.1 Geographical Markets 5.2 Drivers and Barriers 6 Strategic Consolidations 6.1 Major Co-Development Deals 6.2 Major Licensing Deals 7 Appendix Companies Mentioned - Aptalis Pharma - Chiesi Farmaceutici - Forest Laboratories - Genentech - Gilead Sciences - Insmed - Novartis - PTC Therapeutics - Pharmaxis - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5g...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 0

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 55

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Balavant Insurance Group Welcomes John Jankowski as CIO

Updated Category News Views 317

Leadership Appointment at Balavant Insurance Group Balavant Insurance Group has made a significant move by appointing John Jankowski as its new Chief Information Officer. This announcement marks a pivotal moment for the company, known for its focus on technological advancement and innovative insurance solutions. Strategic Role of the Chief Information Officer In his role,...

Continue Reading
Exploring the Growth of the Industrial Absorbent Sector

Updated Category News Views 245

Understanding the Industrial Absorbent Market Dynamics The industrial absorbent market is poised for remarkable growth, expected to reach $5.50 billion by 2031. This growth trajectory aligns with a compound annual growth rate (CAGR) of 4.3%. The increase in market size is largely driven by the rising usage of absorbents across various industries in response to...

Continue Reading
ChoiceOne Financial Services Achieves Successful Bank Merger

Updated Category News Views 147

Successful Bank Merger by ChoiceOne Financial Services ChoiceOne Financial Services, Inc. (NASDAQ: COFS), the parent company of ChoiceOne Bank, has achieved a significant milestone by completing the consolidation of The State Bank into ChoiceOne Bank. This strategic move empowers the strength of ChoiceOne, further enhancing its service capabilities and market presence. A...

Continue Reading
Danantara Indonesia and INA Forge Nickel Investment Alliance with Eramet

Updated Category News Views 443

Strategic Collaboration for Nickel Development In a significant move to bolster the nickel downstream industry, partners including Danantara Indonesia and the Indonesia Investment Authority (INA) have officially signed a Memorandum of Understanding (MoU) with the prominent French mining company, Eramet. This collaboration aims to create an extensive investment platform...

Continue Reading
Full Moon Bar-B-Que's Generous Initiative for Local Kids

Updated Category News Views 180

Full Moon Bar-B-Que's Generosity In a heartwarming gesture, Full Moon Bar-B-Que has made a significant impact on the community by contributing $200,000 worth of backpacks and school supplies. Their ongoing commitment through the Backpack Blessings program is not just about donations; it's about nurturing and empowering local children who need support the most. Supporting...

Continue Reading